New Platform Accelerates VR Cybersickness Research

Summary: A first-of-its-kind study utilizing a remote research platform has launched to investigate cybersickness, one of virtual reality’s most persistent technical and clinical barriers. Cybersickness occurs due to a classic sensory-motor conflict, where the high-fidelity visual motion tracked inside a headset mismatches the user’s physical, stationary bodily orientation.

To overcome the scaling limitations of traditional laboratory environments, researchers are leveraging the Virtual Experience Research Accelerator (VERA). Funded by the National Science Foundation (NSF), this innovative platform enables investigators to conduct large-scale, complex immersive technology trials remotely. By deploying a standardized digital testing protocol directly to participants’ home environments, the platform achieves in days what historically required months of localized, one-on-one laboratory monitoring.

Key Facts

The Scaling Breakthrough: VERA gathered data from over 250 remote participants in just 15 cumulative days (including 90 in the first 72 hours), starkly outpacing the original in-lab study that was limited to just 30 individuals.
The “Cybersicker” Protocol: Participants undergo a specialized 30-minute immersive session using their own Meta Quest headsets, experiencing a controlled virtual carnival ride engineered to provoke and track motion symptoms.
Granular Data Collection: The automated protocol captures subjective sickness ratings every 30 seconds alongside continuous, objective hardware head-tracking data, visual acuity metrics, and pre- and post-exposure surveys.
Target Enrollment: The active study aims to reach a total cohort of 2,000 remote participants to uncover wide-scale individual variations in biological susceptibility.
Cross-Sector Impact: Solving the sensory mismatches that drive cybersickness is essential for expanding safe VR applications across clinical healthcare, education, industrial workforce training, and general digital accessibility.

Source: UCF

A first-of-its-kind research study leveraging remote participants to study cybersickness at unprecedented scale and speed has launched with the Virtual Experience Research Accelerator (VERA), a National Science Foundation-funded platform designed to advance immersive technology research.

Cybersickness, one of VR’s most persistent challenges, occurs when symptoms such as nausea, dizziness and discomfort are caused by a mismatch between visual motion in a headset and a user’s physical motion.

This shows a woman in a VR headset. — The VERA platform utilizes decentralized consumer hardware to study the precise individual variations in cybersickness susceptibility at a speed and scale previously impossible in localized labs. Credit: Neuroscience News

“Understanding who is susceptible to cybersickness is critical to improving VR accessibility, making VR more comfortable for all users and enabling broader adoption across research, education and industry,” says Gerd Bruder, associate professor at the University of Central Florida who is leading the study in collaboration with other university researchers and external partners.

Early data collection has highlighted the powerful capabilities of the VERA platform to accelerate VR research.

In just 15 cumulative days, more than 250 participants completed the full study protocol, including more than 90 participants in the first three days. Each participant completed a standardized, approximately 30-minute session remotely using their own Meta Quest headset from home.

In comparison, the original in-lab study collected data from just 30 participants. In traditional VR research settings, studies with hundreds of participants often require several months to complete.

The study protocol includes a controlled VR carnival ride experience, called the “Cybersicker,” periodic sickness ratings collected every 30 seconds, pre- and post-exposure questionnaires, an in-VR visual acuity assessment, and continuous head-tracking data.

Enrollment is ongoing with a target of 2,000 participants. Preliminary analyses already suggest meaningful individual differences in how quickly and severely participants experience cybersickness. Further findings will be shared as the study progresses.

“VERA was built to study problems like this with a combination of speed, scale, and experimental complexity not previously possible,” says Gregory Welch, the lead principal investigator on VERA at UCF. “This is just the beginning. The sectors where VERA can make an impact is expansive, from healthcare to workforce training to accessibility to learning.”

Key Questions Answered:

Q: What exactly causes cybersickness inside a virtual reality environment?

A: Cybersickness is fundamentally triggered by a sensory mismatch or “prediction error” within the brain’s spatial orientation systems. When you wear a VR headset, your visual system registers rapid movement, such as riding a virtual roller coaster, and signals to your brain that you are moving. However, the vestibular system in your inner ear and the proprioceptive receptors in your muscles signal that you are sitting perfectly still. This profound conflict between visual motion and physical position rapidly manifests as nausea, dizziness, and intense systemic discomfort.

Q: How does the VERA platform manage to collect complex scientific data from a user’s home?

A: The platform bridges the physical gap by transforming consumer VR hardware into remote scientific data hubs. Participants log into a standardized app on their personal Meta Quest headsets from home. The platform then takes over to deliver a highly controlled 30-minute protocol. While the user experiences the virtual ride, the software automatically interrupts every 30 seconds to collect real-time symptom ratings, measures visual changes inline, and continuously streams precise head-tracking coordinates back to the research team.

Q: Why is expanding the scale of this research to 2,000 participants so critical for the VR industry?

A: Small laboratory studies often fail to capture the full spectrum of human biological diversity, leading to generalized conclusions. Preliminary data from this large-scale trial already show massive individual differences in how quickly and severely people experience motion symptoms. By building a massive database of ,2000 diverse users, researchers can pinpoint exactly why certain populations are highly susceptible while others are resilient. This granular insight is critical for engineers to design customized accessibility profiles, specialized software mitigation filters, and safer hardware standards across healthcare, training, and education.